Axogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Axogen and other ETFs, options, and stocks.About AXGN
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.
AXGN Key Statistics
Stock Snapshot
Axogen(AXGN) stock is priced at $33.32, giving the company a market capitalization of 1.54B. It carries a P/E multiple of -680.00.
On 2025-12-07, Axogen(AXGN) stock moved within a range of $32.91 to $33.92. With shares now at $33.32, the stock is trading +1.2% above its intraday low and -1.8% below the session's peak.
Trading activity shows a volume of 838.01K, compared to an average daily volume of 1.1M.
The stock's 52-week range extends from a low of $9.22 to a high of $34.24.
The stock's 52-week range extends from a low of $9.22 to a high of $34.24.
AXGN News
TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $39 from $26 and keeps a Buy rating on the shares after the company announced that the FDA ha...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application for Avance, an acellular nerve scaff...
Analyst ratings
100%
of 10 ratingsMore AXGN News
Axogen has reported that the FDA has approved the Biologics License Application for AVANCE, an acellular nerve allograft for treating peripheral nerve discontin...
TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...
(RTTNews) - Axogen, Inc. (AXGN) announced that the U.S. Food and Drug Administration has approved the Biologics License Application (BLA) for AVANCE, an acellul...
